Kernel Capital confirms, that through The Bank of Ireland Kernel Capital Growth Fund II it has completed a further significant investment in Dundalk-based Nova Leah. This investment is part of a substantial round that includes new investor Northwell Ventures, the investment arm of Northwell Health, New York State’s largest healthcare provider. Additional funding has also been provided Sure Valley Ventures and Enterprise Ireland. The investment round will enable Nova Leah, who also have offices in the US, significantly expand its market reach. Kernel Capital is Nova Leah’s largest institutional shareholder. Denise Sidhu, Partner, Kernel Capital will join the board of Nova Leah. The terms of this transaction are undisclosed.

Nova Leah customers already include many of the world’s top medical device manufacturers. The Company has won international awards for its cloud-based security product SelectEvidence® which ensures that connected medical devices are continuously assessed for cybersecurity vulnerabilities.

“We are delighted to welcome Northwell Health as investors to Nova Leah, with over 800 hospitals and medical centres in the US Northwell Health are a strategically important partner. This latest transaction builds upon the significant commercial partnerships that Nova Leah have already established.”
Denise Sidhu, Partner, Kernel Capital

“We are delighted to welcome Northwell Health on board, given their outstanding reputation for both market innovation and patient safety. We are excited to partner with Northwell to apply our product IP to the Healthcare Delivery market. This investment combined with investment from our existing investors Kernel Capital and Sure Valley Ventures will have a significant impact on our ability to enter new markets and scale effectively.”
Dr. Anita Finnegan, CEO, Nova Leah


About Nova Leah:
Nova Leah is a world leader in the provision of cybersecurity solutions for medical device manufacturers and healthcare providers. With offices in the US and in Ireland, Nova Leah’s software helps connected medical device manufacturers meet cybersecurity compliance requirements throughout the entire product lifecycle. Nova Leah’s flagship product, SelectEvidence® is an expert cybersecurity risk assessment platform that guides medical device manufacturers through the processes of identifying applicable threats to their products and implementing the right security controls to mitigate them.
Nova Leah was founded by Dr. Anita Finnegan, government advisor and award-winning international expert in cybersecurity risk management. Finnegan is a published author and project leader of multiple, internationally regulated, industry standards for medical equipment in healthcare technology. For more information go to